Barclays Maintains an 'Overweight' on Halozyme Therapeutics (HALO); Underappreciated Assets Plus Possible Partnership On Deck
Tweet Send to a FriendGet Alerts HALO Hot Sheet
Price: $6.32 -1.4%
Rating Summary:
6 Buy, 0 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 2 | New: 2
Rating Summary:
6 Buy, 0 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 2 | New: 2
Trade HALO Now!
Barclays maintains an 'Overweight' on Halozyme Therapeutics (NASDAQ: HALO) price target of $15.00.
Analyst, Ying Huang, attended the American Diabetes Association (ADA) conference this past week in which Halozyme presented data for several studies, most regarding diabetes.
Huang said, "PH20 results appear promising; positive reception from physicians. We note increasing interest in HALO's proprietary insulin program, with key opinion leaders highlighting PH20 as a promising technology."
Huang thinks the next step for the company if is to enter a strategic partnership with Novo Nordisk (NYSE: NVO), Saonfi (NYSE: SNY) or Eli Lilly (NYSE: LLY) for the prandial insulin side, and enter a strategic partnership with the dominant insulin pump manufacturer (Medtronics (NYSE: MDT), who owns ~70% market share) on the pump insulin side.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $8.12 yesterday, with a 52 week range of $5.54-$13.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ying Huang, attended the American Diabetes Association (ADA) conference this past week in which Halozyme presented data for several studies, most regarding diabetes.
Huang said, "PH20 results appear promising; positive reception from physicians. We note increasing interest in HALO's proprietary insulin program, with key opinion leaders highlighting PH20 as a promising technology."
Huang thinks the next step for the company if is to enter a strategic partnership with Novo Nordisk (NYSE: NVO), Saonfi (NYSE: SNY) or Eli Lilly (NYSE: LLY) for the prandial insulin side, and enter a strategic partnership with the dominant insulin pump manufacturer (Medtronics (NYSE: MDT), who owns ~70% market share) on the pump insulin side.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $8.12 yesterday, with a 52 week range of $5.54-$13.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Adobe (ADBE) Posts Positive Creative Cloud Subscriber Surprise in Q2 - Jefferies
- UPDATE: Bernstein Cuts BlackBerry (BBRY) to Underperform; Notes Weak BB10 Traction
- UPDATE: BofA/Merrill Lynch Upgrades Adobe (ADBE) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ChangeRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
